Traders should monitor the June 18, 2026 FDA decision as a key catalyst; the strong cash position and reduced burn rate improve the company's runway and reduce near-term dilution risk, while the GSK partnership de-risks commercialization. The sharp improvement in profitability and revenue, driven by collaboration inflows, suggests improved financial sustainability pending regulatory outcome.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 27 $2.33entry
- T+1 · 8mo ago −3.86%α −3.50% · $2.24
- T+5 · 8mo ago +12.02%α +8.15% · $2.61
- T+20 · 7mo ago +14.59%α +1.85% · $2.67
- T+60 · 5mo ago −7.51%α −23.58% · $2.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177% YoY revenue increase to $41.3M in the quarter, primarily from collaboration payments with GSK and Pfizer, while R&D expenses dropped 80% due to reduced trial activity. The company also announced that the FDA set a PDUFA date of June 18, 2026, for tebipenem HBr, an investigational oral antibiotic for cUTI, with cash reserves of $40.3M expected to fund operations into 2028.
Key Financial Metrics
Key Facts
- Net income of $31.5M in Q4 2025 vs. net loss of $(20.9)M in Q4 2024
- Total revenue of $41.3M in Q4 2025, up from $15.0M in Q4 2024 (175% YoY growth)
- Full-year 2025 revenue of $66.8M vs. $48.0M in 2024
- R&D expenses fell to $5.6M in Q4 2025 from $28.8M in Q4 2024 due to completion of the PIVOT-PO trial
- FDA set PDUFA date of June 18, 2026, for tebipenem HBr NDA resubmission for cUTI
- Cash and equivalents: $40.3M as of Dec 31, 2025, expected to fund operations into 2028
- Received $25M milestone payment from GSK in Q1 2026 for NDA resubmission
Financial Impact
Revenue increased by $18.8M annually and $26.3M quarterly, while R&D costs decreased by $58.3M annually, leading to a $77.1M improvement in net income year-over-year
Risk Factors
- FDA approval of tebipenem HBr is not guaranteed and could be delayed or denied
- Future revenue depends heavily on milestone and collaboration payments, which are non-recurring
- Commercial success depends on GSK's execution, over which Spero has limited control
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263404 |
Track record
17 reports on SPRO
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +8.06% at T+1 after the Jun 17, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers